Overcoming innate immune barriers that impede AAV gene therapy vectors
Open accessThe DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The field of gene therapy has made considerable progress over the past several years. Adeno-associated virus (AAV) vectors have emerged as promising and attractive tools for in vivo gene therapy. Despite the recent clinical successes achieved with recombinant AAVs (rAAVs) for therapeutics, host immune responses against the vector and transgene product have been observed in numerous preclinical and clinical studies. These outcomes have hampered the advancement of AAV gene therapies, preventing them from becoming fully viable and safe medicines. The human immune system is multidimensional and complex. Both the innate and adaptive arms of the immune system seem to play a concerted role in the response against rAAVs. While most efforts have been focused on the role of adaptive immunity and developing ways to overcome it, the innate immune system has also been found to have a critical function. Innate immunity not only mediates the initial response to the vector, but also primes the adaptive immune system to launch a more deleterious attack against the foreign vector. This Review highlights what is known about innate immune responses against rAAVs and discusses potential strategies to circumvent these pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“further supported with the reports of complement-mediated TMA cases in subjects receiving high doses of systemic AAV (40, 41)”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the goal of commonly used immunomodulation regimes was to inhibit T cell function and included mostly corticosteroids, sirolimus, tacrolimus, mycophenolate mofetil, or cyclosporine (40, 41).”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, rAAV capsid-targeting TLR2, various DNA sensors, and complement activation may also play a role (22).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“Figure 1, activated IRAKs lead to transcription of several proinflammatory cytokines, including TNF-α and IL-6 (35).”
BackgroundPattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895 · cited 1×
“These signals lead to the expression of host defense genes, like the MHC genes, proinflammatory cytokines, chemokines, and type I and III IFNs (31).”
BackgroundCyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Kawai, T., & Akira, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.006 · Cited by 3,658 · cited 1×
“TLRs that have been implicated in initiating inflammatory responses to viruses are TLR2 (glycoproteins and lipoproteins), TLR3 (dsRNA), TLR4 (glycoproteins and bacterial LPS), TLR7 (ssRNA), TLR8 (ssRNA), and TLR9 (unmethylated CpG [cytosine-phosphate-guanine] DNA) (39).”
BackgroundRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297 · cited 2×
“Secreted cytokines and chemokines are also critical for inducing effective adaptive and memory immune responses (33).”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233 · cited 4×
“TLR1, 2, 4, 5, 6, and 10 (glycoprotein-recognizing receptors) are commonly located on the cell surface, whereas TLR3, 7, 8, and 9 (nucleic acid–specific receptors) are generally found on the endosomal membrane (38).”
BackgroundInfluentialSTING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“Mice deficient in cGAS and STING are more susceptible to lethal herpes simplex virus 1 (HSV1) infection because of a decrease in type I IFN response (71, 72).”
BackgroundIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
Self-citationAIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
Hornung, V., Ablasser, A., Charrel-Dennis, M., Bauernfeind, F., Horvath, G., Caffrey, D. R., Latz, E., & Fitzgerald, K. A. (2009) · Nature · doi:10.1038/nature07725 · Cited by 2,627 · cited 14×
“Further studies are required to elucidate whether AAV infection activates the AIM2 inflammasome pathway.”
BackgroundInfluentialSelf-citationAdeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citation
Research works printed but not linked: 6
- Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy. Press release. Audentes Therapeutics. August 20, 2020. https://www.audentestx.com/press_release/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy/ Accessed November 2, 2020
- Pfizer’s new phase 1b results of gene therapy in ambulatory boys with duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Press release. Pfizer. May 15, 2020. https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-Dystrophy-DMD-Support-Advancement-into-Pivotal-Phase-3-Study/default.aspx Accessed November 2, 2020
- Chan, 2019, Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome, Mol Ther, 27
- Letizia, 2019, Engineering AAV vectors to reduce CD8+ T cell responses following intramuscular injection in mice, Mol Ther, 27
- Pfizer presents initial clinical data on phase 1b gene therapy study for duchenne muscular dystrophy (DMD). Press release. Pfizer. June 28, 2019. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd Accessed November 2, 2020
- Solid Biosciences provides SGT-001 program update. Press release. Solid Biosciences. November 12, 2019. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Accessed November 2, 2020
Cited by
Items 101–200 of 212
Nanocarrier design for pathogen-inspired innate immune agonist delivery
Kane, G. I., Brassil, M. L., Diaz-Infante, M. B., & Atukorale, P. U. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.07.007 · Cited by 11
Matsuzaka, Y., Hirai, Y., Hashido, K., & Okada, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031551 · Cited by 9
Portero, V., Deng, S., Boink, G. J. J., Zhang, G., de Vries, A. A. F., & Pijnappels, D. A. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13744 · Cited by 9
“Alter-natively, viral vector-specific antibodies can be removed by plasmapheresis or immunoabsorption [98, 99, 103].”
BackgroundInfluentialStrategies to target the central nervous system HIV reservoir
Mastrángelo, A., Gama, L., & Cinque, P. M. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000847 · Cited by 8
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Deborah, R., Cavedon, A., Siddiqui, S., Rice, L., Finn, P. F., et al. (2024) · Cells · doi:10.3390/cells13231979 · Cited by 8
Advances in Duchenne Muscular Dystrophy: Diagnostic Techniques and Dystrophin Domain Insights
Sarvutienė, J., Ramanavičius, A., Ramanavičius, S., & Prentice, U. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083579 · Cited by 10
“This immune attack on transduced cells could result in a transient or permanent loss of the therapeutic dystrophin protein expression [210,211].”
Handyside, B., Zhang, L., Yates, B., Xie, L. Y., Ismail, A. M., Murphy, R., Baridon, B., Su, C., Bouwman, T., Mangini, L., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.065 · Cited by 8
Penaud‐Budloo, M., Lecomte, É., Lecomte, Q., Pacouret, S., Broucque, F., Guy‐Duché, A., Dupont, J.-B., Jeanson, L., Robin, C., Blouin, V., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101305 · Cited by 6
Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells
Patra, A. T., Tan, E., Kok, Y. J., Ng, S. K., & Bi, X. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101278 · Cited by 8
Preexisting maternal immunity to AAV but not Cas9 impairs in utero gene editing in mice
Riley, J. S., Luks, V. L., Berkowitz, C. L., Dumitru, A. M., Kus, N. J., Dave, A., Menon, P. V., Paepe, M. E. D., Jain, R., Li, L., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179848 · Cited by 8
“Preexisting immunity to the naturally derived components of gene editing technology, including delivery vehicles and bacte-ria-based editing enzymes, remains a barrier to the broad successful translation of therapeutic gene editing (28, 29).”
Current regulatory requirements for assessment of immunogenicity for gene therapy medicinal products
Mann, C. J., Giblin, J., Braun, M., Schmid, F., Sørensen, M. R., Caferra, P., Hudák, A., Letoha, T., Coderch, N., Hickling, T. P., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102422 · Cited by 7
“26,27 For example, fever, cytokine release, and elevated alanine transaminase (ALT) levels early (within 24 h) after AAV administration have been suggested to be the result, in part, of innate immune activation.”
Liu, Z., & Song, S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102911 · Cited by 7
“175,180 In trials for spinal muscular atrophy and other systemic indications, patients receiving high-dose AAV vector have developed acute liver injury, thrombocytopenia, and thrombotic microangiopathy.”
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
“Vector modification to attenuate or eliminate the ITR promoter function could reduce dsRNA formation and diminish the immune response triggered by TLR3 activation [145].”
Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus
Sato, T., Chaugule, S. R., Greenblatt, M. B., Gao, G., & Shim, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.034 · Cited by 5
“83 Despite these potential immunological concerns, rAAV vectors generally exhibit low immunogenicity, making them an attractive platform for in vivo transgene delivery by cotreating with immunosuppressors.”
Self-citationFredlund, F., Fryklund, C., Trujeque-Ramos, O., Staley, H. A., Pardo, J., Luk, K. C., Tansey, M. G., & Swanberg, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106841 · Cited by 5
AAV-mediated inner ear gene delivery triggers mild host immune responses in the mammalian inner ear
Ishibashi, Y., Zhu, J., Gernoux, G., Yu, Y., Suh, M. J., Isgrig, K. T., Grati, M., Olszewski, R. T., Hoa, M., Liang, C., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101456 · Cited by 9
“9,40,41 The human inner ear was previously considered to be immune privileged due to its relatively isolated anatomical location.”
Masri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 6
“In contrast, capsid protein epitopes can be detected by other TLR that do not detect nucleic acids, such as TLR1, 2, 4, 5 and 6 [19].”
BackgroundRecent Advances in Canine Medicine
Fonseca‐Alves, C. E. (2022) · Veterinary medicine and science · doi:10.5772/intechopen.100825 · Cited by 6
Porter, J. M., Oswald, M. S., Sharma, A., Emmanuel, S. N., Kansol, A., Bennett, A. D., McKENNA, R. V., & Smith, J. G. (2023) · Journal of Virology · doi:10.1128/jvi.00060-23 · Cited by 8
Enhanced Discriminability of Viral Vectors in Viscous Nanopores
Tsutsui, M., Tsunekawa, Y., Wada, M., Arima, A., Onodera, A., Nishina, M., Nagoya, M., Baba, Y., Kawai, T., & Okada, T. (2025) · Small Methods · doi:10.1002/smtd.202401321 · Cited by 8
A synthetic platform for developing recombinant adeno‐associated virus type 8 producer cell lines
Lin, Y., Kuo, H., Lu, M., Mahl, T., Aslanidi, G., & Hu, W. (2025) · Biotechnology Progress · doi:10.1002/btpr.70009 · Cited by 7
Myocardial infarction creates a critical time window for AAV-based cardiac gene transfer
Chen, G., Zhang, Y., Liu, Z., Wu, J., Chen, Z., Yang, L., Zhang, J., Wu, Y., Li, J., Bai, B., et al. (2025) · Fundamental Research · doi:10.1016/j.fmre.2025.06.012 · Cited by 4
“These data ruled out immune responses in the MI-mediated AAV-enhancing effect and supported immune suppression as an important component in AAV administration [ 32 , 33 ].”
Immunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 6
“Toll-like receptor 2 has been shown to bind to the AAV capsid upon entry into cells, while the CpG motifs contained within the inverted terminal repeats (ITRs) of the AAV ssDNA can bind TLR9 in the endosome or lysosome while entering the cell [10].”
Kochs, T., Nath, P., Chen, A. J., Romee, R., & Maia, A. (2026) · Advanced Science · doi:10.1002/advs.75326 · Cited by 4
Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy
Perez, M. L., & Weisleder, N. L. (2026) · Genes · doi:10.3390/genes17050533 · Cited by 3
“Innate immune recognition of bacterial nucleases (including pre-existing adaptive immunity to commonly used Cas orthologs) further reinforces the need for transient expression strategies and careful selection of editing enzymes [95,96].”
Huang, X., Wang, X., Feng, L., Zhou, R., Chen, W., Jiang, X., Lv, F., Xu, W., Xu, X., Xie, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123742 · Cited by 3
Half-Life Extension Enhances Drug Efficacy in Adeno-Associated Virus Delivered Gene Therapy
Wu, H., Hu, D. M., Li, Q., Wang, C., Zhu, X., Li, W., Chen, B., Ji, P., Huang, K., Huang, A., et al. (2022) · Engineering · doi:10.1016/j.eng.2022.02.009 · Cited by 4
Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections
Mnyandu, N., Jacobs, R., Arbuthnot, P. B., & Maepa, M. B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111360 · Cited by 3
“Upon infection, AAVs induce the host’s innate and adaptive immunity in a mechanism similar to most viruses, as has been extensively reviewed before [40–42].”
Burgaz, S., Navarro, E., Rodríguez-Carreiro, S., Navarrete, C. M., Garrido‐Rodríguez, M., Lastres‐Becker, I., Chocarro, J., Lanciego, J. L., Muñóz, E., & Fernández‐Ruíz, J. (2024) · Behavioral and Brain Functions · doi:10.1186/s12993-024-00256-9 · Cited by 3
Intravitreal AAV2 gene delivery to feline retinal ganglion cells
Oikawa, K., Eaton, J. S., Kiland, J. A., Torné, O., Mathu, V., Nickells, R. W., & McLellan, G. J. (2024) · Vision Research · doi:10.1016/j.visres.2024.108519 · Cited by 3
“…interventions to induce ocular hypertension and/or model glaucomatous RGC damage may cause inflammatory responses and therefore dampen transduction efficiency by viral vectors delivered to retinal cells, as previous studies suggested (Ail et al., 2022; Kotterman et al., 2015; Muhuri et al., 2021).”
Xiao-ping, H., Wang, X., Sun, Y., Xie, X., Xiao, L., Xu, Y., Yan, Q., Xu, X., Li, L., Xu, W., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70308 · Cited by 3
Prinzipien der translationalen Gentherapie für neuromuskuläre Erkrankungen
Schoser, B. G. H. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01287-1 · Cited by 3
“Dies ist möglich, da das AAV-Genom inWirtszellen durch homologe Rekombination langer Ketten (Konkatemere/Kokatemerisierung) zwischen ihren ITR-Sequenzenunterzogen wird [16].”
BackgroundInfluentialThe Diversity of Parvovirus Telomeres
Laugel, M., Lecomte, É., Ayuso, E., Adjali, O., Mével, M., & Penaud‐Budloo, M. (2022) · Veterinary medicine and science · doi:10.5772/intechopen.102684 · Cited by 4
AAV vector immunotoxicity: Stopping the domino effect
Asokan, A. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.016 · Cited by 3
Latest Developments in Gene Therapy for Heart Failure
Olandt, C. A., Kelso, C., Hong, K. N., & Greenberg, B. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01066-y · Cited by 2
“Pre-existing NAbs elicit an acute humoral response associated with complement activation that is separate from the non-specific innate immune response triggered by recognition of viral epitopes or the antibody mediated adaptive immune response [79, 80].”
Ni, X., Liu, H., Ji, X., Chen, Z., Chen, X., Luo, Y., Chen, W., & Yang, S. (2025) · Acta Oto-Laryngologica · doi:10.1080/00016489.2025.2492366 · Cited by 5
“Clinical data suggest that host immune responses to AAV components—particularly capsid proteins and transgene products—may curtail sustained trans-gene expression [6,7].”
Navigating the Hurdles of Intra-Articular AAV Gene Therapy
Li, W., Thornton, O. R., Feng, S. L., & Li, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010123 · Cited by 2
“The result is opsonization, phagocyte recruitment, and, in some settings, direct lysis [56].”
Tissue‐specific gene delivery approaches
Nasr, S. S., Cheema, Y., Stern, A., Tabah, O., Poore, S., & Duncan, G. A. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70125 · Cited by 4
“142,143 An epidemiology study conducted by Cal-cedo et al. found that neutralizing antibodies affected different AAV serotypes to varying degrees, and that the presence of neutralizing antibodies greatly hindered AAV-mediated transduction.”
Mukalel, A. J., Tylek, T., Geisler, H. C., O’Brien, E. M., Frazee, C. P., Li, J. J., Thatte, A. S., Safford, H. C., Figueroa‐Espada, C. G., Alameh, M., et al. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70138 · Cited by 6
Gasperetti, A., Calkins, H. G., & Barth, A. S. (2026) · Heart Rhythm · doi:10.1016/j.hrthm.2026.03.1942 · Cited by 2
Henry, T. D., Chung, E. S., Alvisi, M., Murray, D. R. P., Traverse, J. H., Roessig, L., Roberts, L., Sanganalmath, S. K., Reddy, S., Ervin, L., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag105 · Cited by 3
Re-administration of AAV-mediated gene therapy for OTOF-related deafness: a single-arm trial
Fan, X., Zhang, L., Gao, Z., Han, L., Yang, P., Wang, D., Yu, H., Cao, Q., Jiang, L., Chen, X., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04505-4 · Cited by 2
“Equally concerning, AAV re-administration may amplify innate immune and/or complement activation, increasing immune-related toxicity 35 .”
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 5
Muhuri, M., & Gao, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.29189.mmu · Cited by 2
Self-citationClinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery
Henshey, B., Carneiro, A., Lei, K., Schaffer, D. V., & Boulis, N. M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.004 · Cited by 3
Nanovaccine enables complement system inhibition and high-dose AAV re-administration
Liao, Z., Yu, J., Liang, F., Liu, Y., Zhao, Z., Wang, Y., Shi, X., Wang, Y., & Liu, H. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160810 · Cited by 2
Hoyle, B., Bello, D., Hill, J., Das, S., & Kim, J. (2025) · Current Gene Therapy · doi:10.2174/0115665232369708250327081305 · Cited by 2
Jäschke, N. M., & Büning, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.04.002 · Cited by 2
Donfrancesco, A. D., Adelizzi, A., Giri, A., Duchi, R., Boito, S., Barandalla, M., Massaro, G., Santanatoglia, C., Cappellozza, E., Perota, A., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00551-8 · Cited by 2
Enrichment of full AAV capsids by preparative strong anion exchange chromatography
Subramanian, S., Dembek, M., Auchus, N., Hines, A. R., Devine, P. W. A., Hagner-McWhirter, Å., Maloisel, J., & Linke, T. A. (2025) · Biotechnology Progress · doi:10.1002/btpr.70065 · Cited by 1
“6 Furthermore, competitive binding of empty cap-sids to receptors on target cells may require higher overall rAAV capsid doses to achieve the desired therapeutic effect.”
Wu, Z., Liu, H., & Wu, D. (2025) · Medical Oncology · doi:10.1007/s12032-025-03158-6 · Cited by 1
“Furthermore, pre-existing neutralizing antibodies (NAbs) in TME against AAV capsids form immune complexes cleared by phago - cytes in the liver and spleen, reducing target tissue distribu - tion [49 ].”
Gene Therapy for Cardiomyopathy: Tools, Targets, and Trials
Agarwal, R. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013361 · Cited by 1
Long-term restoration of auditory function in a DFNA2 mouse model by adenine base editing
Kong, Y., Zhang, Y. L., Xie, E., Li, X., Peng, Z., Zhang, J., Zhao, Y., & Yuan, H. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00433-5 · Cited by 2
“…and sustained transgene expression may activate innate and adaptive immune pathways (Chan et al, 2022; Hosel et al, 2012; Ishibashi et al, 2023; Muhuri et al, 2021; Chandler et al, 2019; Liu and Xu, 2023; Rai et al, 2020) and disturb proteostasis (Kim et al, 2006; Lange et al, 2016; Yasuno et…”
Sakai, A., Sugiyama, M., Onodera, M., Fukushima, F., Tanaka, M., Uchiyama, T., Mizokami, M., & Sumazaki, R. (2026) · Liver International · doi:10.1111/liv.70760 · Cited by 2
“The rapid and uniform phenomena observed immediately after onasemnogene abeparvovec infusion suggest rapid activation of the monocyte–macrophage system as a common reaction, likely triggered by the host innate immune response to the large quantity of administered AAV vector [10].”
Analysis of Exon Skipping Applicability for Dysferlinopathies
Leckie, J., Rodriguez, S. H., Krahn, M., & Yokota, T. (2025) · Cells · doi:10.3390/cells14030177 · Cited by 1
“Additional safety risks include the development of innate and adaptive immune responses and the potential genomic consequences of viral genome insertion [60,61].”
Mechanisms of AAV neutralization by human alpha-defensins
Porter, J. M., Hulce, K. R., Oswald, M. S., Busuttil, K., Emmanuel, S. N., Bennett, A. D., McKenna, R., & Smith, J. G. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013283 · Cited by 2
“However, poor transduction efficiency and interactions with the host immune system present hurdles that must be overcome to produce more efficient vectors [6,7,9,10].”
Herring, S. K., & Rodgers, B. D. (2025) · Gene Therapy · doi:10.1038/s41434-025-00578-x · Cited by 1
Xu, Y., Bai, X.-N., Lin, J., Lu, K., Weng, S., Wu, Y., Liu, S., Li, W., Chen, G., & Li, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.15.612566 · Cited by 1
Mechanisms of AAV neutralization by human alpha-defensinsPreprint
Porter, J. M., Hulce, K. R., Oswald, M. S., Busuttil, K., Emmanuel, S. N., Bennett, A. D., McKENNA, R. V., & Smith, J. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614754 · Cited by 1
Duchenne muscular dystrophy treatment with lentiviral vector containing mini-dystrophin gene in vivoPreprint
He, Z., Wang, X., Zhu, Y., Liu, T., Zhou, L., Fu, Y., Zhao, J., Li, Y., Zheng, Y., Yang, X., et al. (2023) · doi:10.22541/au.167706007.78963220/v1
Touramanidou, L., Gurung, S., Cozmescu, A. C., Perocheau, D. P. B., MOULDING, D. A., Ridout, D. A., Cavedon, A., Siddiqui, S., Rice, L. M., Finn, P. F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.26.550697
“Macrophage 90 activation following AAV vector administration has been reported [31].”
BackgroundAge-related disease: Effective intervention
Fossel, M., & Cooke, J. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00013-x
Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Tran, N. M., Xu, X., Qi, L. S., & Hu, Y. (2024) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-99-4436-1_19 · Cited by 1
Strategies on Gene Therapy in Progressive Myoclonus Epilepsies
Kayani, S. N., Gumusgoz, E., Minassian, B. A., & Dolce, A. M. (2024) · doi:10.1093/med/9780197549469.003.0052
Preclinical development of viral vector gene therapies
Newman, M. S., Hudry, E., Brassard, J. A., & Cunningham, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00003-1
Hope Unlocked: Gene Therapy with Viral Vectors and Gene Editing
Thiaville, J. J., Dias, M. S., Kato, S. E. M., Basak, S., Rengarajan, S., Silva, H. P., Rivas, N., & D’Costa, S. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-81787-8_5
Bio-Genetics and Disease: Diagnostic and Analytical Approaches
Juma, M., Jasab, S. J. H., Mohammed, S. H. H., & Alai, L. H. S. (2025) · Bright Sky Publications eBooks · doi:10.62906/bs.book.388
rAAV-Mediated Gene Therapy Targeting CNS Disorders
Suárez-Amarán, L., Chatzi, C. A., Flier, I., & Samulski, R. J. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_2
Dai, Y., Banks, G. B., Wu, G., Lévesque, P., Jawa, V., & Kozhich, A. T. (2025) · Human Gene Therapy · doi:10.1177/10430342251374689
SARS ‐ CoV ‐2 Nucleocapsid Protein Does Not Induce Inflammation in Endothelial Cells or Monocytes
Tufail, M., Lu, X., Barr, S. D., Borradaile, N. M., & Feng, Q. (2025) · The FASEB Journal · doi:10.1096/fj.202501433r
“However, AAV and LVV vectors are well known to activate innate immune responses [37].”
Pal, P., Naskar, R., Paul, B., Oruganti, S., & Chakraborty, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01279
Choi, S. J., Koch, R. L., Gibson, R. A., Weaver, F. E., Adhikari, Y., Eisner, W., Mehta, A., Jeck, W. R., Lim, J., & Kishnani, P. S. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.11.006
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049039
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049054
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049060
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049048
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049051
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049045
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049063
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049042
Fritzen, L., Wienken, K., Wagner, L., Kurtyka, M., Vogel, K., Körbelin, J., Weggen, S., Fricker, G., & Pietrzik, C. U. (2024) · Figshare · doi:10.6084/m9.figshare.27049057
Zhang, Y., ZHU, Z., Li, Z., Feng, J., Long, J., Deng, Y., Ahmed, W., Khan, A. A., Huang, S., Fu, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27132726
Adeno-associated virus-induced neurotoxicity is prevented by CpG depletion
Dunn, C. E., Carvajal, B. V., Ma, J., Castaneda-Hernandez, G., Nguyen, A. V., Jung, C., Suriano, C. M., & Boulanger, L. M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201703 · Cited by 1
“7,8,27,28 Consistent with TLR9’s role in initiating transgene-limiting immune responses, reducing TLR9 activation is associated with more robust and persistent transgene expression.”
Nakatsuka, R., Matsumoto, K., Liu, Y., Takeda, K., Tsunaka, Y., Torisu, T., Yamaguchi, Y., & Uchiyama, S. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05430
Healing the Liver: Cell and Gene Therapies for Inherited and Acquired Diseases
Borroni, E., Cirsmaru, R. A., Follenzi, A., & Merlin, S. (2026) · Livers · doi:10.3390/livers6020018
“…a T-cell-mediated and innate immunity (via TLR9 receptors)-mediated liver inflammation characterized by elevated plasma levels of liver enzymes (ALT/GPT and AST/GOT), which can compromise the duration of therapy and which is usually managed pharmacologically with corticosteroids [128–130].”
Optimized AAVrh10 and Factor 9 vectors demonstrate improved phenotypic rescue in hemophilia B mice
Huda, S., Senthilkumar, M. B., Bihani, D., Sarangi, P., Kumar, G. N., Chandra, D., & Jayandharan, G. R. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109655
Past, Present and Future of Regenerative Gene Therapy for Ischemic Heart Failure
González, L. F., Bouwman, M., & Bakkers, J. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10731-x
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244 · Cited by 2
“16 Mice lacking C3 convertases, have delayed anti-AAV Ab development and signi fi cantly lowered NAb titers, highlighting the important role of the complement system in mediating the immune response to AAV.”
InfluentialAAV vectors for cancer gene therapy
Lee, M., Park, J., Park, J. H., & Curiel, D. T. (2026) · Advances in cancer research · doi:10.1016/bs.acr.2026.02.005
Nan, X., Sun, J., Jiao, Y., Li, W., Chen, Y., Liu, Y., Xu, B., Yu, L., Guo, W., & Wu, Y. (2026) · Human Gene Therapy · doi:10.1177/10430342261432669 · Cited by 1
“36,84,95,96 Therefore, rational immune-modulation strategies are essential to sustain therapeutic transgene expression and improve safety pro fi les.”
Guo, Y., Huang, J., Zhang, Y., Huang, Y., Li, Z., Xie, Y., Cao, Y., Qian, K., Bai, F., Li, W., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.001
“AAV consists of a single-stranded DNA (ssDNA) genome of approximately 4.7 kb enclosed by a capsid of approximately 26 nm in diameter, and both the AAV capsid and genome serve as immunogenic components 17-19 .”
InfluentialPreclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Insect-Cell-Produced AAV2 Vectors Activate Myeloid Innate Immune Response Featuring NETosis
Liu, X., Zhou, Y., Tang, Z., Li, W., Wei, S., & Han, K. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01772
Epigenetic regulation of transgenes
Mwangi, L., Warga, E., & Elmer, J. J. (2026) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2026.05.015
“While several reviews have summarized the wide range of antiviral host cell defenses (Coroadinha, 2023; Annoni et al., 2019; Follenzi et al., 2000; Muhuri et al., 2021; Prasad et al., 2022; Mano et al., 2015; Colella et al., 2017), and cytosolic DNA sensing pathways (Zahid et al., 2020; Won and…”
Desmeure, V., Geoffroy, M., Coré, S., Faivre, M., Georger, C., Gicquel, E., & Richard, I. (2026) · Research Square · doi:10.21203/rs.3.rs-9645975/v1
Ramamurthy, R. M., Zheng, W. T., Wachtman, S. E., Diaz, J. H., George, S. K., Simon, T., Zhou, Y., Wan, M., Lu, B., Walker, S. J., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201772
“78 Analysis of key genes involved in hepatotoxicity and inflammation showed that multiple genes were significantly differentially expressed (>1.5-fold) in the hLTEs transduced with either AAV5-CMV-EGFP or AAV3b-CMV-EGFP when compared with hLTE-NT, with each serotype producing a distinct pattern of…”
Influential
Metadata
- Authors
- Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2021-01-04
- Volume
- 131
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC7773343
- OpenAlex
- W3120585537
- Cited by
- 212
- References
- 172
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 59 · 2023: 30 · 2022: 28 · 2021: 11
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Institutes of Health (AI067497)
- National Heart, Lung, and Blood Institute (P01HL131471, R01HL097088, UG3HL147367)
- National Institute of Allergy and Infectious Diseases (R01AI132296, R33AI136007, R01AI067497, R01AI128358, R37AI067497, P01AI100263, R01AI141181, U19AI149646, R56AI067497)
- National Institute of Neurological Disorders and Stroke (R01NS076991)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus vectors, recombinant adeno-associated virus, innate immunity, immune evasion, gene therapy vectors, host immune response, in vivo gene therapy, immunogenicity
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Humans, Immunity, Innate, Genetic Therapy, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.